Nasofan (Fluticasone Propionate)

Fluticasone propionate binds to glucocorticoid receptors in nasal epithelial cells, altering gene transcription to suppress inflammatory cytokines, chemokines, and other mediators. This reduces swelling, mucus production, and immune cell infiltration, leading to improved nasal airflow and symptom control.

The prescribed dose of Nasofan is determined by the treating clinician based on the patient’s age, severity of symptoms, and response to therapy. The prescriber will provide specific instructions on the number of sprays per nostril and the frequency of administration.

Safety data for fluticasone propionate in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Nasofan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Nasofan’s active ingredient, fluticasone propionate, is a high‑potency corticosteroid with minimal systemic absorption compared with some older agents. It offers once‑daily dosing for many patients and a favorable safety profile when used as directed, making it a common choice for allergic rhinitis and nasal polyps.

Nasofan should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid freezing the product.

Nasofan is a nasal spray. The patient gently shakes the bottle, primes it if required, tilts the head slightly forward, inserts the nozzle into one nostril, and sprays the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if instructed.

Serious risks, though rare, include adrenal suppression with prolonged high‑dose use, cataracts or glaucoma, severe allergic reactions, and nasal septal perforation. Patients should report any visual changes, persistent nosebleeds, or signs of systemic corticosteroid effects to their healthcare provider promptly.

Nasofan should be avoided in individuals with known hypersensitivity to fluticasone propionate or any component of the formulation, in children younger than two years, and in patients with active, untreated nasal infections unless directed by a physician.